News | July 31, 2024
Boehringer Ingelheim acquires Nerio Therapeutics for US$ 1.3bn
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
Access to breast milk for sick newborns admitted in intensive care units plays a lifesaving role
The inspection scope included 6 separate Biologics manufacturing units comprising 4 Drug Substance and 2 Drug Product manufacturing plants
Campaign launched to spread awareness regarding dengue prevention and control
Laurus Labs has reported total income of Rs. 1,197.42 crores during the period ended June 30, 2024
The inspection was concluded with two 483 observations
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
The discussion at the fourth session was centered on the fusion of academic rigor and industrial pragmatism as a key to pioneering solutions for sustainable and prosperous future
The product is bioequivalent and therapeutically equivalent to the reference listed drug
The drug will be manufactured at the group's formulation manufacturing facility in Ahmedabad SEZ - II, India
Subscribe To Our Newsletter & Stay Updated
